Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta-analysis of a shifting treatment paradigm.
A gentler chemotherapy approach combining two drugs achieves remission and one-year survival rates comparable to or better than intensive treatments in younger leukemia patients.
This meta-analysis of 429 younger AML patients showed that HMA plus venetoclax achieves high remission rates and 75% one-year survival, outperforming historical intensive chemotherapy benchmarks. These results support prospective randomized trials comparing this lower-intensity regimen to standard induction in fit younger patients.
What the study was
- Study design
- Systematic review and meta-analysis (8 studies, 429 patients)
- Population
- Younger AML patients (mean age 54)
- Sample size
- 429
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Cancer
Why it surfaced
First major meta-analysis of HMA+venetoclax specifically in younger/fit AML patients, showing outcomes that challenge the IC-only paradigm with 75% 1-year OS.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.